MSN Labs launches a new drug for percutaneous coronary intervention

MSN Labs launches a new drug for percutaneous coronary intervention
MSN Labs launches a new drug for percutaneous coronary intervention

MSN Labs launches a new drug for percutaneous coronary intervention

 

· A bioequivalent generic, CANREALTM injection (Cangrelor) is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revarscularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

 

Hyderabad, 01 October 2021: MSN Laboratories, one of country’s leading, fully integrated research-based Pharmaceutical organizations with expertise spanning across the domains of APIs, Finished Dosages and Branded Generics (Prescription Medicines) became the first company to launch the generic CANREALTM injection (Cangrelor) in India.

 

The bioequivalent generic CANREALTM (Cangrelor) is the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition developed to overcome both delayed and prolonged anti platelet activity. The drug was approved by DCGI (Drug Controller General of India) recognizing the unmet need for intravenous rapidly acting, reversible antiplatelet agent in the country. It is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

 

The launch of the product coincided with a mega cardiology CME organized by MSN Labs to commemorate World Heart Day in Hyderabad where Dr Deepak Bhatt, principal investigator of CHAMPION TRIAL and a few of country’s leading cardiologists illumined the audience with their insightful presentations on “ Antiplatelet Therapy Featuring Cangrelor P2Y12 Inhibitor". The event was attended by over 3,000 cardiologists from all over India.

 

MSN Group commented: “This launch signifies MSN Labs’ commitment to bring access to new, affordable and diverse therapeutic options, swiftly and consistently, for helping the world overcome life-threatening diseases. The organization is hopeful that this drug will prove to be highly advantageous for both patients and medical fraternity in terms of treatment outcomes, safety and efficacy.”

 

The product which comes in a single-use 10 mL vial containing 50 mg Cangrelor as a lyophilized powder for reconstitution, is manufactured at FDA and EU approved state-of-the-art injectable facility in Hyderabad. It is available at all retail/hospital attached pharmaceutical outlets and is dispensed upon a prescription by a cardiologist.

 

For more information and availability CANREALTM (Cangrelor) reach out to customercare@msnlabs.com.

 

 

 

***END***

 

 

 

About MSN Group:

 

MSN Group is the fastest growing research-based and fully integrated pharmaceutical company headquartered in Hyderabad, India. Founded in 2003 with a mission to make healthcare affordable, MSN has nine API and five finished dosage facilities in India & USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.

 

 

 

For information on MSN Labs, please visit www.msnlabs.com